# Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

> **NCT00962715** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Influenza Vaccine Trivalent Inactivated (TIV)
- **DRUG:** Pegylated interferon (PEGrIFN-α, Pegasys)
- **DRUG:** Interferon (IFNα, Roferon-A)

## Key facts

- **NCT ID:** NCT00962715
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962715, "Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00962715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*